LimmaTech Biologics Acquired by Lilly for Bacterial Vaccines
LimmaTech Biologics Acquired by Lilly for Next-Generation Bacterial Vaccines
Swiss clinical-stage biotech company LimmaTech Biologics AG has entered a definitive agreement to be acquired by Lilly. The company develops vaccines against bacterial pathogens with rising antimicrobial resistance, including Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis.
Lead Program: Staphylococcus aureus Vaccine
LimmaTech's lead candidate LTB-SA7 is in Phase 1 development targeting S. aureus, the leading cause of surgical-site infections. The platform targets toxins and superantigens to generate broad, durable immune responses.
Deal Terms
Lilly will acquire LimmaTech for up to $780 million in cash, including an upfront payment and milestone-based payments. The transaction underscores the growing need for vaccine-based prevention strategies amid rising antimicrobial resistance.
Strategic Significance
Daniel Skovronsky, Lilly's chief scientific officer, stated: 'Staphylococcus aureus is one of the most consequential bacterial pathogens, and LimmaTech's approach of targeting toxins may help prevent infections before they occur.' The acquisition combines LimmaTech's innovative platform with Lilly's global development and manufacturing capabilities.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.
More Headlines
Tokyo Core Inflation Slows, Remains Below BOJ Target
Tokyo Core Inflation Slows, Remains Below BOJ Target
…Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
…Australian Pension Fund HUB24 Faces Regulatory Scrutiny
Australian Pension Fund HUB24 Faces Regulatory Scrutiny
…